1[1]Rocha R,Williams GH.Rationale for the use of aldostenrone antagonists in congestive heart failure.Drugs,2002,62 (5):723-731.
2[2]Hayashi M,Tsutamoto T,Wada A,et al.Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.Circulation,2003,107(20):2559-2565.
3[3]Bauersachs J,Heck M,Fraccarollo D,et al.Addition of spironolact-one to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction:role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.J Am Coll Cardiol,2002,39 (2):351-358.
1Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
